Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-22T23:37:59.982Z Has data issue: false hasContentIssue false

9 - Current therapeutic approaches

Published online by Cambridge University Press:  27 August 2009

Mark A. Feitelson
Affiliation:
Thomas Jefferson University, Philadelphia
Get access

Summary

Therapeutic decisions in chronic HCV infection have been made difficult by the subclinical nature of most acute and chronic infections. This is because, in many cases, infections are not even detected unless anti-HCV or HCV RNA tests are performed (Section 1.6 and Ch. 19). This does not lessen the danger of chronic HCV, which often does not become symptomatic until the development of cirrhosis some 20 years following infection. Given the high morbidity and mortality associated with cirrhosis, combined with the insidious nature and variable progression of CLD, it is not surprising that so many chronically infected patients are not treated until liver disease is fairly advanced and considerable permanent damage is done. For example, patients that become symptomatic and then present with cirrhosis may already be in end-stage liver disease. Such patients are also at very high risk for the development of HCC (Chs. 4 and 6). Given these considerations, HCV is often not diagnosed for a long period after virus exposure, since patients are ‘well’ and do not seek medical help. This represents one of the major challenges in treating HCV infection.

IFN-α is one of a family of naturally occurring glycoproteins that have both direct antiviral and immunomodulatory activities. Initially, IFN-α was obtained from leukocyte cultures in very limited quantities, but the availability of recombinant IFN-α in the 1980s finally permitted large-scale, controlled trials of its utility.

Type
Chapter
Information
Hepatitis C Virus
From Laboratory to Clinic
, pp. 101 - 106
Publisher: Cambridge University Press
Print publication year: 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×